Insider trade

CEO exercised or converted 29K REGN derivative securities

Traded Dec 31, 2025 · Filed Jan 5, 2026

Regeneron PharmaceuticalsREGN

29K
Shares

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 31, 2025
Reporting period: Not applicable
Filed with the SEC: Jan 5, 2026

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001218629-26-000002
Filed / recorded

Jan 5, 2026, 10:53 PM UTC

Added to OQRO

Oct 2, 2026, 12:28 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

REGENERON PHARMACEUTICALS, INC.

Issuer CIK

872589

Ticker

REGN

Reporting person

Leonard S Schleifer

Relationship

Director, Officer

Officer title

Bd. Co-Chair, President & CEO

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Dec 31, 2025

Transaction code

M

Shares / units

28,570

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

243,093

Ownership form

Direct

Amendment

No

Around the same time

9mo ago

1,500Shares · @ $374.12

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

Director sold ~$1.2M of Regeneron Pharmaceuticals

Scheduled in advance9mo ago

9mo ago

1,500Derivative units

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

Why it stands out

Dates, kept separate

Context

Source receipt

Around the same time

1,500Shares · @ $374.12

1,500Derivative units

Most active this month